☰

Ashwini Devkota - Publications

Affiliations: 
2006-2011 Medicinal Chemistry University of Texas at Austin, Austin, Texas, U.S.A. 
Tree Info Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Sammons RM, Devkota AK, Kaoud TS, Warthaka M, Cho EJ, Dalby KN. Steady State and Time-Dependent Fluorescent Peptide Assays for Protein Kinases. Current Protocols. 4: e998. PMID 38439594 DOI: 10.1002/cpz1.998  0.819
2020 Cho EJ, Devkota AK, Stancu G, Edupunganti R, Debevec G, Giulianotti M, Houghten R, Powis G, Dalby KN. A Robust and Cost-Effective Luminescent-Based High-Throughput Assay for Fructose-1,6-Bisphosphate Aldolase A. Slas Discovery : Advancing Life Sciences R & D. 2472555220926146. PMID 32462959 DOI: 10.1177/2472555220926146  0.752
2019 Veloria J, Shin M, Devkota AK, Payne SM, Cho EJ, Dalby KN. Developing Colorimetric and Luminescence-Based High-Throughput Screening Platforms for Monitoring the GTPase Activity of Ferrous Iron Transport Protein B (FeoB). Slas Discovery : Advancing Life Sciences R & D. 2472555219844572. PMID 31039677 DOI: 10.1177/2472555219844572  0.525
2018 Devkota AK, Veloria JR, Guo HF, Kurie JM, Cho EJ, Dalby KN. Development of a High-Throughput Lysyl Hydroxylase (LH) Assay and Identification of Small-Molecule Inhibitors against LH2. Slas Discovery : Advancing Life Sciences R & D. 2472555218817057. PMID 30589612 DOI: 10.1177/2472555218817057  0.559
2018 Veloria JR, Devkota AK, Cho EJ, Dalby KN. Development of a cost effective and robust AlphaScreen platform for application. Biotechniques. 64: 181-183. PMID 29661010 DOI: 10.2144/Btn-2018-2001  0.481
2017 Jose J, Tavares CDJ, Ebelt ND, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KN. Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. Acs Medicinal Chemistry Letters. 8: 1072-1076. PMID 29057053 DOI: 10.1021/Acsmedchemlett.7B00282  0.771
2017 Cho EJ, Devkota AK, Stancu G, Edupunganti R, Powis G, Dalby KN. A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase. Slas Discovery. 2472555217726325. PMID 28820953 DOI: 10.1177/2472555217726325  0.746
2017 Guo HF, Cho EJ, Devkota AK, Chen Y, Russell W, Phillips GN, Yamauchi M, Dalby KN, Kurie JM. A scalable lysyl hydroxylase 2 expression system and luciferase-based enzymatic activity assay. Archives of Biochemistry and Biophysics. PMID 28216326 DOI: 10.1016/J.Abb.2017.02.003  0.543
2016 Veloria JR, Devkota AK, Cho EJ, Dalby KN. Optimization of a Luminescence-Based High-Throughput Screening Assay for Detecting Apyrase Activity. Journal of Biomolecular Screening. PMID 27821623 DOI: 10.1177/1087057116675859  0.562
2016 Grandjean G, De Jong PR, James BP, Koh MY, Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, Edupuganti R, Devkota A, Stancu G, Liddington RC, Dalby KN, et al. Definition of a novel feed-forward mechanism for glycolysis-HIF1α signaling in hypoxic tumors highlights adolase A as a therapeutic target. Cancer Research. PMID 27261507 DOI: 10.1158/0008-5472.Can-16-0401  0.769
2016 Rycaj K, Cho EJ, Liu X, Chao HP, Liu B, Li Q, Devkota AK, Zhang D, Chen X, Moore J, Dalby KN, Tang DG. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells. Oncotarget. PMID 26871947 DOI: 10.18632/Oncotarget.7303  0.548
2016 Tavares CD, Devkota AK, Dalby KN, Cho EJ. Application of Eukaryotic Elongation Factor-2 Kinase (eEF-2K) for Cancer Therapy: Expression, Purification, and High-Throughput Inhibitor Screening. Methods in Molecular Biology (Clifton, N.J.). 1360: 19-33. PMID 26501899 DOI: 10.1007/978-1-4939-3073-9_2  0.817
2016 Ebelt ND, Taveres CDJ, Xie X, Naguib YW, Jose J, Ruwona TB, Devkota AK, Park J, Kaoud TS, Anslyn EV, Chang JT, Cui Z, Bartholomeusz C, Dalby KN. Abstract 3774: KD06 is a novel anti-cancer drug that causes cell death in triple-negative breast cancer cell lines and tumor xenografts Cancer Research. 76: 3774-3774. DOI: 10.1158/1538-7445.Am2016-3774  0.782
2015 Jong PRd, Grandjean GV, Devkota AK, Cho EJ, Dalby KN, Powis G. Abstract 4448: Identification of a small molecule inhibitor of aldolase A for the targeting of hypoxic cancer cells Cancer Research. 75: 4448-4448. DOI: 10.1158/1538-7445.Am2015-4448  0.352
2015 Sammons RM, Kaoud TS, Devkota AK, Cho EJ, Dalby KN. Abstract 3648: A high-throughput fluorescence anisotropy screening for discovery of inhibitors that target the D-recruitment site of ERK in vitro and in cells Cancer Research. 75: 3648-3648. DOI: 10.1158/1538-7445.Am2015-3648  0.84
2014 Devkota AK, Edupuganti R, Yan C, Shi Y, Jose J, Wang Q, Kaoud TS, Cho EJ, Ren P, Dalby KN. Reversible covalent inhibition of eEF-2K by carbonitriles. Chembiochem : a European Journal of Chemical Biology. 15: 2435-42. PMID 25224652 DOI: 10.1002/Cbic.201402321  0.811
2014 Wang Q, Park J, Devkota AK, Cho EJ, Dalby KN, Ren P. Identification and validation of novel PERK inhibitors. Journal of Chemical Information and Modeling. 54: 1467-75. PMID 24745945 DOI: 10.1021/Ci500114R  0.778
2014 Devkota AK, Warthaka M, Edupuganti R, Tavares CD, Johnson WH, Ozpolat B, Cho EJ, Dalby KN. High-throughput screens for eEF-2 kinase. Journal of Biomolecular Screening. 19: 445-52. PMID 24078616 DOI: 10.1177/1087057113505204  0.82
2014 Tavares CDJ, Jose J, Devkota AK, Park J, Kaoud TS, Anslyn EV, Dalby KN. Abstract 5462: Antiproliferative and cytotoxic activities of 5-(nonyloxy)tryptamine derivatives in breast cancer cells Cancer Research. 74: 5462-5462. DOI: 10.1158/1538-7445.Am2014-5462  0.784
2012 Kaoud TS, Yan C, Mitra S, Tseng CC, Jose J, Taliaferro JM, Tuohetahuntila M, Devkota A, Sammons R, Park J, Park H, Shi Y, Hong J, Ren P, Dalby KN. From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules. Acs Medicinal Chemistry Letters. 3: 721-725. PMID 23002419 DOI: 10.1021/Ml300129B  0.795
2012 Devkota AK, Tavares CD, Warthaka M, Abramczyk O, Marshall KD, Kaoud TS, Gorgulu K, Ozpolat B, Dalby KN. Investigating the kinetic mechanism of inhibition of elongation factor 2 kinase by NH125: evidence of a common in vitro artifact. Biochemistry. 51: 2100-12. PMID 22352903 DOI: 10.1021/Bi201787P  0.792
2012 Tavares CD, O'Brien JP, Abramczyk O, Devkota AK, Shores KS, Ferguson SB, Kaoud TS, Warthaka M, Marshall KD, Keller KM, Zhang Y, Brodbelt JS, Ozpolat B, Dalby KN. Calcium/calmodulin stimulates the autophosphorylation of elongation factor 2 kinase on Thr-348 and Ser-500 to regulate its activity and calcium dependence. Biochemistry. 51: 2232-45. PMID 22329831 DOI: 10.1021/Bi201788E  0.755
2012 Kaoud TS, Yan C, Tseng C, Jose J, Devkota AK, Taliaferro J, Ren P, Dalby K. Abstract 4776: From in-silico screening to anti-cancer activity: The discovery of a potent inhibitor targeting the JNK-JIP interaction Cancer Research. 72: 4776-4776. DOI: 10.1158/1538-7445.Am2012-4776  0.824
2012 Abramczyk O, Tavares CDJ, Devkota AK, Ryazanov AG, Turk BE, Riggs AF, Ozpolat B, Dalby KN. Corrigendum to "Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli" [Protein Expression and Purification 79 (2011) 237-244] (DOI:10.1016/j.pep.2011.05.005) Protein Expression and Purification. DOI: 10.1016/J.Pep.2012.07.010  0.783
2011 Abramczyk O, Tavares CD, Devkota AK, Ryazanov AG, Turk BE, Riggs AF, Ozpolat B, Dalby KN. Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli. Protein Expression and Purification. 79: 237-44. PMID 21605678 DOI: 10.1016/J.Pep.2011.05.005  0.81
2011 Kaoud TS, Devkota AK, Harris R, Rana MS, Abramczyk O, Warthaka M, Lee S, Girvin ME, Riggs AF, Dalby KN. Activated ERK2 is a monomer in vitro with or without divalent cations and when complexed to the cytoplasmic scaffold PEA-15. Biochemistry. 50: 4568-78. PMID 21506533 DOI: 10.1021/Bi200202Y  0.736
2011 Piserchio A, Warthaka M, Devkota AK, Kaoud TS, Lee S, Abramczyk O, Ren P, Dalby KN, Ghose R. Solution NMR insights into docking interactions involving inactive ERK2. Biochemistry. 50: 3660-72. PMID 21449613 DOI: 10.1021/Bi2000559  0.753
2010 Devkota AK, Kaoud TS, Warthaka M, Dalby KN. Fluorescent peptide assays for protein kinases. Current Protocols in Molecular Biology / Edited by Frederick M. Ausubel ... [Et Al.]. Unit 18.17. PMID 20583097 DOI: 10.1002/0471142727.Mb1817S91  0.813
Show low-probability matches.